Stem cell transplant after best response in some T-cell lymphomas
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies whether doing an autologous stem cell transplant (using your own stem cells) after a complete response helps people with certain T-cell lymphomas stay in remission longer. It may be an option if your lymphoma has shrunk completely and you fit the safety and testing requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to under 70 years old when you sign consent
- Your doctor says you are healthy enough for an autologous stem cell transplant
- You have a specific nodal T-cell lymphoma subtype (not previously treated) with a measurable tumor
- Your blood counts and organ tests meet minimum safety thresholds (transfusions are allowed)
- You do not have certain lymphoma types (for example ALK-positive lymphoma, nasal type, and several skin lymphomas)
- You have no brain/meninges involvement and you can follow the study schedule
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two types of stem cell transplants (from a donor or your own cells) for people with certain T-cell lymphomas who had only a partial response to first chemotherapy. It aims to see which approach may work better.
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
This trial is for people with certain T-cell lymphomas that did not respond or got worse after initial chemotherapy. It offers a personalized treatment plan, possibly including a stem cell transplant, based on how your disease behaved after first-line therapy.
This trial tests a combination of two drugs (cidabenamine and azacitidine) to help prevent peripheral T-cell lymphoma from coming back after a donor stem cell transplant. It is for patients who are at high risk of progression and have already had a transplant.
This trial tests whether high-dose chemotherapy followed by a stem cell transplant using your own cells can help people with certain types of peripheral T-cell lymphoma live longer. You would qualify if you have already finished your first round of chemotherapy and are in complete remission.
This trial compares two types of stem cell transplants for adults with T-cell lymphoblastic lymphoma that has spread (stage III or IV) and has gone into remission after 3 rounds of chemo. The goal is to see which transplant approach works better.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.